OverviewSuggest Edit

AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. It develops drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology. The company offers its products to primary care and specialty care physicians through distributors and local representative offices.

TypePublic
Founded1999
HQCambridge, GB
Websiteastrazeneca.com
Employee Ratings4.2
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)70,600(+10%)
Job Openings1,989
Revenue (FY, 2019)$24.4 B(+11%)
Share Price (May 2021)£77.3
Cybersecurity ratingBMore

Key People/Management at AstraZeneca

Pascal Soriot

Pascal Soriot

Executive Director and CEO
Marc Dunoyer

Marc Dunoyer

Executive Director and Chief Financial Officer
Katarina Ageborg

Katarina Ageborg

Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca Sweden
Pam Cheng

Pam Cheng

Executive Vice-President, Operations and Information Technology
Ruud Dobber

Ruud Dobber

Executive Vice-President, BioPharmaceuticals Business Unit
David Fredrickson

David Fredrickson

Executive Vice-President, Oncology Business Unit
Show more

AstraZeneca Office Locations

AstraZeneca has offices in Cambridge, Harlow, London, Luton and in 106 other locations
Cambridge, GB (HQ)
1 Francis Crick Ave
Cambridge, GB
136 Hills Rd
Harlow, GB
Lovet Rd
London, GB
15 Stanhope Gate
London, GB
2 Kingdom St
Luton, GB
600 Capability Green
Show all (118)

AstraZeneca Financials and Metrics

AstraZeneca Revenue

Embed Graph
View revenue for all periods
AstraZeneca's revenue was reported to be $24.38 b in FY, 2019 which is a 10.4% increase from the previous period.
USD

Revenue (Q3, 2020)

6.6b

Gross profit (Q3, 2020)

5.2b

Gross profit margin (Q3, 2020), %

79.2%

Net income (Q3, 2020)

651.0m

EBIT (Q3, 2020)

1.2b

Market capitalization (7-May-2021)

101.5b

Closing stock price (7-May-2021)

77.4

Cash (30-Sept-2020)

8.1b

EV

115.8b
AstraZeneca's current market capitalization is £101.5 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

22.5b22.1b24.4b

Revenue growth, %

(2%)(2%)10%

Cost of goods sold

4.3b4.9b4.9b

Gross profit

18.1b17.2b19.5b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.4b5.1b6.2b5.2b5.2b5.3b5.5b5.8b6.4b6.4b6.3b6.6b

Cost of goods sold

894.0m950.0m1.2b1.1b1.0b1.2b1.1b1.1b1.4b1.4b984.0m1.4b

Gross profit

4.5b4.1b5.0b4.0b4.1b4.2b4.4b4.8b5.1b4.9b5.3b5.2b

Gross profit Margin, %

83%81%80%78%80%78%79%82%79%78%84%79%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

3.3b4.8b5.4b

Accounts Receivable

2.8b3.0b3.6b

Inventories

3.0b2.9b3.2b

Current Assets

13.2b15.6b15.6b
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

2.9b2.1b1.2b

Depreciation and Amortization

3.0b3.8b3.8b

Inventories

(548.0m)(13.0m)(316.0m)

Accounts Payable

415.0m(103.0m)868.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Depreciation and Amortization

658.0m1.3b1.9b709.0m1.4b2.1b676.0m1.4b2.1b841.0m1.6b2.4b

Cash From Operating Activities

88.0m338.0m2.6b(140.0m)(75.0m)394.0m(387.0m)491.0m1.6b139.0m1.2b3.0b

Purchases of PP&E

(286.0m)(549.0m)(849.0m)(213.0m)(486.0m)(728.0m)(174.0m)(438.0m)(659.0m)(186.0m)(370.0m)(598.0m)

Cash From Investing Activities

(146.0m)(351.0m)(686.0m)273.0m177.0m36.0m328.0m(789.0m)(715.0m)9.0m157.0m(423.0m)
USDQ1, 2017

Debt/Equity

1.2 x

Debt/Assets

0.3 x

Financial Leverage

4.1 x
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Projects in R&D Pipeline

99133146132144149167171

Phase I Trials Projects

3324444150383435

Phase II Trials Projects

2711333637435042

Phase III Trials Projects

1911352723222725
Show all operating metrics

AstraZeneca Acquisitions / Subsidiaries

Company NameDateDeal Size
Alexion PharmaceuticalsDecember 12, 2020$39 b
Takeda Respiratory BusinessMay 10, 2016$575 m
AcertaPharmaDecember 17, 2015$4 b
ZS PharmaNovember 06, 2015$2.7 b
AlmirallJuly 30, 2014
Pearl TherapeuticsJune 10, 2013$1.2 b
Omthera PharmaceuticalsMay 29, 2013$323 m
Ardea BiosciencesApril 23, 2012$781 m
Guangdong BeiKang Pharmaceutical Company LtdDecember 08, 2011
NovexelDecember 23, 2009
Show more

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 10.7% from Other Disease Areas, 22.1% from Respiratory, Inflammation and Autoimmunity, 35.5% from Oncology, 28.3% from Cardiovascular and Metabolic Diseases and 3.4% from Other

AstraZeneca revenue breakdown by geographic segment: 17.1% from Continental Europe, 38.3% from Americas, 37.2% from Asia, Africa & Australasia and 7.5% from UK

Human Capital Metrics

Embed Graph
Show all human capital metrics

AstraZeneca Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

AstraZeneca Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

AstraZeneca Online and Social Media Presence

Embed Graph

AstraZeneca Company Culture

  • Overall Culture

    B

    70/100

  • CEO Rating

    B

    70/100

  • Compensation

    A

    78/100

  • Diversity

    B

    70/100

Learn more on Comparably

AstraZeneca News and Updates

Astrazeneca shareholders in row over chief executive’s £2.3m bonus hike

Astrazeneca shareholders have been plunged into a bitter row over plans to hike chief executive Pascal Soriot’s pay by £2.3m. The post Astrazeneca shareholders in row over chief executive’s £2.3m bonus hike appeared first on CityAM.

Here’s Why The U.K. Is Offering Under-40s Alternatives To The AstraZeneca Covid-19 Vaccine

The British health agency had previously advised under-30s to seek a different vaccine.

Breaking: EU looking into reports of rare nerve disorder after Astrazeneca vaccine

The EU’s medicines regulator is investigating reports of a rare nerve-degenerating disorder in people who have received Astrazeneca’s Covid-19 vaccine, it The post Breaking: EU looking into reports of rare nerve disorder after Astrazeneca vaccine appeared first on CityAM.

Ghana Gets Second Batch of AstraZeneca Vaccines From Covax

Ghana Gets Second Batch of AstraZeneca Vaccines From Covax

: Under-40s to be offered alternative COVID-19 vaccines to AstraZeneca in U.K.: reports

People under the age of 40 in the U.K. will be offered an alternative to the AstraZeneca COVID-19 vaccine as a precautionary measure, following concerns of rare blood clots linked to the shot, several news media outlets reported on Thursday.

Under-40s in Britain to be offered alternative to Astrazeneca vaccine

People under the age of 40 in Britain will be offered an alternative to the Astrazeneca coronavirus vaccine following concerns of The post Under-40s in Britain to be offered alternative to Astrazeneca vaccine appeared first on CityAM.
Show more

AstraZeneca Frequently Asked Questions

  • When was AstraZeneca founded?

    AstraZeneca was founded in 1999.

  • Who are AstraZeneca key executives?

    AstraZeneca's key executives are Pascal Soriot, Marc Dunoyer and Katarina Ageborg.

  • How many employees does AstraZeneca have?

    AstraZeneca has 70,600 employees.

  • What is AstraZeneca revenue?

    Latest AstraZeneca annual revenue is $24.4 b.

  • What is AstraZeneca revenue per employee?

    Latest AstraZeneca revenue per employee is $345.4 k.

  • Who are AstraZeneca competitors?

    Competitors of AstraZeneca include Daiichi Sankyo, Boehringer Ingelheim and Sanofi.

  • Where is AstraZeneca headquarters?

    AstraZeneca headquarters is located at 1 Francis Crick Ave, Cambridge.

  • Where are AstraZeneca offices?

    AstraZeneca has offices in Cambridge, Harlow, London, Luton and in 106 other locations.

  • How many offices does AstraZeneca have?

    AstraZeneca has 118 offices.